This page contains information for researchers and sponsors of clinical trials and research projects during the ongoing 2019–20 coronavirus pandemic (COVID-19), which is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
Information on the coronavirus
Sponsors, investigators and project leaders of clinical trials and research projects in Switzerland must ensure that the studies are conducted in line with the COVID-19 Ordinance 2 (available in German (PDF), French (PDF) and Italian (PDF), issued by the federal government on 16 March 2020.
In particular, participants over the age of 65 and participants with underlying medical
Information on the corona virus
virus also does not stop at the ethics commissions. Not all the scheduled
committee meetings can be held regularly at the various locations. This means
that there may be delays in the decision-making process and therefore deadlines
cannot always be met. The ethics committees thank you for your understanding.
Nevertheless, the reviews and approvals of studies investigating the disease or investigational medicinal products for COVID-19 are of course treated with priority.
We thank you for your cooperation in this critical situation. In individual cases, the ethics committees are available to answer questions on this matter directly.